Non-Invasive Imaging for Diabetic Retinopathy

The summary for the Non-Invasive Imaging for Diabetic Retinopathy grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Non-Invasive Imaging for Diabetic Retinopathy: Diabetes is a prototypical chronic disease that imposes a large public health burden. One of its many complications is diabetic retinopathy (DR). Early detection of DR is an important problem because many Americans with diabetes do not get regular eye exams due mainly to distance, geography, and economic status. Studies conducted in the 1980s and 1990s demonstrated that vision loss from DR could be prevented if treatment with laser photocoagulation therapy was initiated based upon regular screening and subsequent diagnosis of retinal disease. In this Request for Applications (RFA) the NEI seeks to develop, apply, and evaluate noninvasive technology that is practical, affordable, and accessible so that patients with diabetes can benefit from remote site disease screening.

Federal Grant Title:	Non-Invasive Imaging for Diabetic Retinopathy
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-EY-04-001
Type of Funding:	Grant
CFDA Numbers:	93.867
CFDA Descriptions:	Vision Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Feb 14, 2005
Posted Date:	Jul 19, 2004
Creation Date:	Jul 19, 2004
Archive Date:	Mar 16, 2005
Total Program Funding:
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinic...; • NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed); • NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed); • NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional); • NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinica...; • Nei Career Transition Award (K22); • NEI Translational Research Program On Therapy For Visual Disorders; • NEI Clinical Study Planning Grant Program (R34)
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...